Seminars in Oncology
Volume 30, Issue 6 , Pages 776-788 , December 2003

Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy

  • Rowan T Chlebowski

      Affiliations

    • Harbor-UCLA Research and Education Institute, Torrance, CA, USA
    • Corresponding Author InformationAddress reprint requests to Rowan T. Chlebowski, MD, PhD, Harbor-UCLA Research and Education Institute, 1124 W Carson St, Bldg J-3, Torrance, CA 90502, USA
    • ,
  • Jung A Kim

      Affiliations

    • Harbor-UCLA Research and Education Institute, Torrance, CA, USA
    • ,
  • Nananda F Col

      Affiliations

    • Decision Symptoms Group and Division of General Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

References 

  1. Pritchard KI. Adjuvant therapy for premenopausal women with breast cancer (Is it time for another paradigm shift?). J Clin Oncol. 2002;20:4611–4614
  2. Henderson IC. A rose is no longer a rose. J Clin Oncol. 2002;20:3365–3368
  3. Goss P, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 2001;19:881–894
  4. Writing Group for the Women’s Health Initiative . Risks and benefits of estrogen plus progestin in healthy postmenopausal women (Principal results from the women’s health initiative randomized controlled trial). JAMA. 2002;288:321–333
  5. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet. 2002;360:942–944
  6. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9:466–472
  7. Jemal A, Murray T, Samuels A, et al.  Cancer statistics 2003. CA Cancer J Clin. 2003;53:5–26
  8. Kroman H, Jensen MB, Wohlfahrt J, et al.  Factors influencing the effect of age on prognosis in breast cancers (Population based study). Br Med J. 2000;320:474–479 Commentary: much still to learn about relations between tumor biology, prognosis, and treatment outcome in early breast cancer
  9. Winer EP, Hudis L, Burstein HJ, et al.  American Society of Clinical Oncology Technology Assessment (The use of aromatase inhibitors as adjuvant therapy for women with hormone receptor positive breast cancer). J Clin Oncol. 2002;20:3119–3131
  10. Early Breast Cancer Trialists’ Collaborative Group . Tamoxifen for early breast cancer (An overview of the randomized trials). Lancet. 1998;351:1451–1467
  11. Goodwin PJ, Ennis M, Pritchard KI, et al.  Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–2370
  12. Nabholtz JM, Pienkowski T, Mackey J, et al.  Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients (Interim analysis of the BICRG 001 study). Proc Am Soc Clin Oncol. 2002;21:141; (abstr)
  13. Goldhirsch A, Gelber RD, Yothers G, et al.  Adjuvant therapy for very young women with breast cancer (Need for tailored treatments). J Natl Cancer Inst. 2001;30:44–51
  14. Klijn JGM, Beex LVAM, Mauriac L, et al.  Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer (A randomized study). J Natl Cancer Inst. 2000;92:903–911
  15. Houghton J, Baum M, Rutqvist L, et al.  The ZIPP trial of adjuvant zoladex in premenopausal patients with early breast cancer (An update at five years). Proc Am Soc Clin Oncol. 2000;19:359; (abstr)
  16. Jonat W, Kaufmann M, Sauerbrei W, et al.  Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer (The Zoladex Early Breast Cancer Research Association Study). J Clin Oncol. 2002;20:4628–4635
  17. Jakesz R, Hausmaninger H, Kubista E, et al.  Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil (Evidence for the superiority of treatment with endocrine blockage in premenopausal patients with hormone-responsive breast cancer). J Clin Oncol. 2002;20:4611–4614
  18. Davidson NE, O’Neill A, Vukov CK, et al.  Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer (An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101)). Proc Am Soc Clin Oncol. 2003;15: (abstr)
  19. Chlebowski RT. Reducing the risk of breast cancer. N Engl J Med. 2000;343:191–198
  20. Chlebowski RT, Col N, Winer EP, et al.  American Society of Clinical Oncology Technology Assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002;20:3328–3343
  21. Henderson BE, Ross R, Bernstein L. Estrogen as a cause of human cancer (The Richard and Hilda Rosenthal Foundation Award lecture). Cancer Res. 1988;48:246–253
  22. Cauley JA, Lucas FL, Kuller LH, et al.  Elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer. Ann Intern Med. 1999;130:270–277
  23. Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy (Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer). Lancet. 1997;350:1047–1059
  24. Ross RK, Paganini-Hill A, Wan PC, et al.  Effect of hormone replacement therapy on breast cancer risk (Estrogen versus estrogen plus progestin). J Natl Cancer Inst. 2000;92:328–332
  25. Chlebowski RT, Hendrix SL, Langer RD, et al.  Estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women (The Women’s Health Initiative randomized trial). JAMA. 2003;289:3243–3253
  26. Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol. 2002;3:303–311
  27. Million Women Study Collaborators . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–427
  28. Pritchard KI, Khan H, Levine M. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer (14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer). Can Med Assoc J. 2002;166:1017–1022
  29. Chlebowski RT, McTiernan A. Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol. 2000;17:130–142
  30. Hulley S, Furberg C, Barrett-Connor E, et al.  Heart and Estrogen/Progestin Replacement Study follow-up (HERS II) (Non cardiovascular disease outcomes during 6–8 years of hormone therapy). JAMA. 2002;288:872–881
  31. US Preventive Services Task Force: Recommendation and rationale. Hormone replacement therapy for primary prevention of chronic conditions. http://www.ahcpr.gov/clinic/3rduspstf/hrt/httrr.htm
  32. Shumaker SA, Legault C, Rapp SR, et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA. 2003;289:2651–2662
  33. Ursic-Vrscaj M, Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol. 1999;25:146–151
  34. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al.  Estrogen replacement therapy after localized breast cancer (Clinical outcome of 319 women followed prospectively). J Clin Oncol. 1999;17:1482–1487
  35. O’Meara ES, Rossing MA, Daling JR, et al.  Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93:754–762
  36. Beckmann MW, Jap D, Djahansouzi S, et al.  Hormone replacement therapy after treatment of breast cancer (Effects on postmenopausal symptoms, bone mineral density and recurrence rates). Oncology. 2001;60:199–206
  37. Durna EM, Wren BG, Heller GZ, et al.  Hormone replacement therapy after a diagnosis of breast cancer (Cancer recurrence and mortality). Med J Aust. 2002;177:340–341
  38. Col NF, Hirota LK, Orr RK, et al.  Hormone replacement therapy after breast cancer (A systematic review and quantitative assessment of risk). J Clin Oncol. 2001;19:2357–2363
  39. Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer (A cohort study). Climacteric. 2002;5:151–155
  40. Stein KD, Jacobsen PB, Hann DM, et al.  Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage. 2000;19:436–445
  41. Ganz PA, Desmond KA, Belin TR, et al.  Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol. 1999;17:2371–2380
  42. Stearns V, Ullmer L, Lopez JF, et al.  Hot flushes. Lancet. 2002;360:1851–1861
  43. Shanafelt TD, Barton DL, Adjel AA, et al.  Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002;77:1207–1218
  44. Fitzpatrick LA, Santen RJ. Hot flashes (The old and new, what is really true?). Mayo Clin Proc. 2002;77:1155–1158
  45. Jacolsen PB, Weitzner MA. Evaluation and management of hot flashes in cancer patients. In:  Berger AM,  Postenay RK,  Weissman DE editor. Principles and Practice of Supportive Oncology. New York, NY: Lippincott Williams & Wilkins; 2002;p. 1–13
  46. Carpenter JS, Johnson D, Wagner L, et al.  Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum. 2002;29:E16–E25
  47. Sloan JA, Loprinzi CL, Novotny PJ, et al.  Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001;19:4280–4290
  48. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flashes. Cochrane Database Syst Rev CD002978. 2001;
  49. Utian WH, Shoupe D, Bachmann G, et al.  Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065–1079
  50. Bertelli G, Venturini M, Del Mastro L, et al.  Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients (A randomized study). Ann Oncol. 2002;13:883–888
  51. Loprinzi CL, Michalak JC, Quella SK, et al.  Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331:347–352
  52. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and menopausal bone loss. Obstet Gynecol. 1999;94:225–228
  53. Cobau CD, Declercq K, Neuberg D, et al.  A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer (A study of the Eastern Cooperative Oncology Group). Cancer. 1991;77:483–489
  54. Segahoff A, Gordon D, Carabasi RE, et al.  Hormonal therapy in cancer of the breast (VII. Effect of conjugated estrogens (equine) on clinical course and hormonal excretion). Cancer. 1954;7:758–763
  55. Smith IE, Ford HT, Gazet JC, et al.  Premarin in the management of metastastic breast carcinoma in postmenopausal patients. Clin Oncol. 1979;5:159–162
  56. Henriksson L, Stjernquist M, Boquist L, et al.  A one-year multicenter of efficacy and safety of continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 1996;174:85–92
  57. Naessen T, Rodriguez-Macias K. Serum lipid profile improved by ultra-low doses of 17beta-estradiol in elderly women. J Clin Endocrinol Metab. 2001;86:2757–2762
  58. Law M, Loprinzi CL, Kugler J, et al.  Double-blind crossover trial of Replens versus KY jelly for treating vaginal dryness and dysparunia in breast cancer survivors. Proc Am Soc Clin Oncol. 1996;15:241; (abstr)
  59. Goldberg RM, Loprinzi CL, O’Fallon JR, et al.  Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994;12:155–158
  60. Pandya KJ, Raubertas RF, Flynn PJ, et al.  Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes (A University of Rochester Cancer Center Community Clinical Oncology Program study). Ann Intern Med. 2000;132:788–793
  61. Vercellini P, Vendola N, Colombo A, et al.  Veralipride for hot flashes during gonadotropin releasing hormone agonist treatment. Gynecol Obstet Invest. 1992;34:102–104
  62. Wesel S, Bourguignon RP, Bosuma WB. Veralipride versus conjugated oestrogens (A double-blind study in the management of menopausal hot flashes). Curr Med Res Opin. 1984;8:696–700
  63. Lebherz TB, French L. Nonhormonal treatment of the menopausal syndrome (A double-blind evaluation of an autonomic system stabilizer). Obstet Gynecol. 1969;33:795–799
  64. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms (A review of randomized, controlled trials). Ann Intern Med. 2002;137:805–813
  65. Chenoy R, Hussains S, Tayob Y, et al.  Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ. 1994;308:501–503
  66. Lieberman S. A review of the effectiveness of Cimifuga racemosa (black cohosh) for the symptoms of menopause. J Women Health Initiat. 1998;7:525–529
  67. Pepping J. “Black cohosh” (Cimifuga racemosa). Am J Health Systems Pharm. 1999;56:1400–1402
  68. Jacobson JS, Troxel AB, Evans J, et al.  Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001;19:2739–2745
  69. Quella SK, Loprinzi CL, Barton DL, et al.  Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors (A North Central Cancer Treatment Group Trial). J Clin Oncol. 2000;18:1068–1074
  70. Van Patten CL, Olivotto IA, Chambers GK, et al.  Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer (A randomized, controlled clinical trial). J Clin Oncol. 2002;20:1449–1455
  71. Hirata JD, Swiersz LM, Zell D, et al.  Does dong quai have estrogenic effects in postmenopausal women? (A double-blind, placebo-controlled trial). Fertil Steril. 1997;68:981–986
  72. Barton DL, Loprinzi CL, Quella SK, et al.  Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16:495–500
  73. Loprinzi CL, Kugler JW, Sloan JA, et al.  Venlafaxine in management of hot flashes in survivors of breast cancer (A randomised controlled trial). Lancet. 2000;356:2059–2063
  74. Loprinzi CL, Sloan JA, Perez EA, et al.  Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20:1578–1583
  75. Barton DL, Loprinzi CL, Sloan SR, et al.  Pilot evaluations of newer antidepressants for hot flashes. Proc Am Soc Clin Oncol. 2002;21:1463; (abstr)
  76. Clayton AH, Pradko JF, Croft HA, et al.  Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63:357–366
  77. Loprinzi CL, Barton DL, Sloan JA, et al.  Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc. 2002;77:1159–1163
  78. Ivarsson T, Spetz AC, Aammar M. Physical exercise and vasomotor symptoms in postmenopausal women. Maturitas. 1998;29:139–146
  79. Ganz PA, Greendale GA, Petersen L, et al.  Managing menopausal symptoms in breast cancer survivors (Results of a randomized controlled trial). J Natl Cancer Inst. 2000;92:1054–1064
  80. Bydder SA, Spry NA. Treatment for hot flashes in women receiving tamoxifen. Med J Aust. 2002;177:266–268
  81. Bond B, Hicota L, Fortium J, et al.  Women like me (Reflection on health and hormones from women treated for breast cancer). J Psychosoc Oncol. 2002;20:39–56
  82. Malenka DJ, Baron JA, Johansen S, et al.  The framing effect of relative and absolute risk. JGIM. 1993;8:543–548
  83. Forrow L, Taylor WC, Arnold RM. Absolutely relative (How researchresults are summarized can affect treatment decisions). Am J Med. 1992;92:121–124
  84. Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ. 1994;309:761–764
  85. Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy (Does the format of efficacy data determine patients’ acceptance of treatment?). Med Decis Mak. 1995;15:152–157

☆ Supported in part by the National Heart, Lung and Blood Institute and Grants No. GCRC m01-RR-00-425 and N01-WH-4-2120 from the National Institutes of Health.

PII: S0093-7754(03)00471-8

doi: 10.1053/j.seminoncol.2003.08.021

Seminars in Oncology
Volume 30, Issue 6 , Pages 776-788 , December 2003

Article Tools